Physician profile
David Benjamin Kay
NPI 1487067484
$4,143.01
in general payments reported to CMS, 2019-2025
21 companies · $1,042 in 2025
The $1,042 reported for 2025 was more than what a typical Glaucoma Specialist provider received nationally (typical 2025 total: $608).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $163 · 2021: $671 · 2022: $343 · 2023: $434 · 2024: $561 · 2025: $1,042.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,019 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,018.85 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $960.90 | 2021-2025 | Idosetr, Idose, Istent Infinite |
| Novartis Pharmaceuticals Corporation | $625.46 | 2019-2021 | |
| Abbvie INC. | $563.31 | 2023-2025 | |
| Alcon Vision LLC | $453.33 | 2021-2025 | Unity, Clareon Panoptix Pro, Hydrus Microstent |
| Allergan, INC. | $448.45 | 2019-2021 | |
| Sight Sciences, INC. | $218.67 | 2022-2025 | Omni Surgical System |
| Johnson & Johnson Surgical Vision, INC. | $141.31 | 2019-2025 | Amo Phaco Needle |
| Bausch & Lomb Americas INC. | $93.73 | 2022-2025 | Vyzulta, Envista Aspire Toric Iol, Lotemax Sm |
| Aerie Pharmaceuticals, INC. | $81.89 | 2019-2021 | |
| Genentech USA, INC. | $81.04 | 2022 | |
| Thea Pharma INC. | $73.41 | 2023-2025 | Iyuzeh |
| New World Medical,INC. | $68.30 | 2024-2025 | Clearpath, Ahmed Glaucoma Valve, Kahook Dual Blade |
| Angiodynamics, INC. | $60.52 | 2020 | |
| Carl Zeiss Meditec, INC. | $57.48 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $50.25 | 2025 | Xdemvy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akorn Operating Company LLC | $40.91 | 2021 | |
| Sun Pharmaceutical Industries INC. | $40.25 | 2019-2020 | |
| Rxsight INC | $24.57 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Kala Pharmaceuticals, INC. | $21.32 | 2019 | |
| Ocular Therapeutix, INC. | $20.31 | 2025 | Dextenza |
| Eyevance Pharmaceuticals LLC | $17.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.